111 related articles for article (PubMed ID: 21316540)
1. Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals.
Ball AT; Xu Y; Sanchez RJ; Shelbaya A; Deminski MC; Nau DP
Clin Ther; 2010 Dec; 32(13):2246-55. PubMed ID: 21316540
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
Bounthavong M; Hsu DI
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
[TBL] [Abstract][Full Text] [Related]
3. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
[TBL] [Abstract][Full Text] [Related]
4. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstein R
Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
[No Abstract] [Full Text] [Related]
6. Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit.
Sullivan J; Tobias JD
Am J Ther; 2006; 13(6):473-7. PubMed ID: 17122526
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomics of linezolid.
Grau S; Rubio-Terrés C
Expert Opin Pharmacother; 2008 Apr; 9(6):987-1000. PubMed ID: 18377341
[TBL] [Abstract][Full Text] [Related]
9. [Linezolid, an agent from a new class of antibiotics].
Kuijper EJ; Schippers EF; Bernards AT
Ned Tijdschr Geneeskd; 2004 Aug; 148(32):1577-81. PubMed ID: 15382556
[TBL] [Abstract][Full Text] [Related]
10. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
11. Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.
You JH; Lee GC; So RK; Cheung KW; Hui M
Infection; 2007 Jun; 35(4):265-70. PubMed ID: 17646907
[TBL] [Abstract][Full Text] [Related]
12. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
Nathwani D
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
14. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.
Vinken A; Li Z; Balan D; Rittenhouse B; Wilike R; Nathwani D
J Hosp Infect; 2001 Dec; 49 Suppl A():S13-24. PubMed ID: 11926436
[TBL] [Abstract][Full Text] [Related]
15. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae.
Isaacson G; Aronoff SC
Int J Pediatr Otorhinolaryngol; 2008 May; 72(5):647-51. PubMed ID: 18321598
[TBL] [Abstract][Full Text] [Related]
16. Role of linezolid in the treatment of orthopedic infections.
Bassetti M; Righi E; Di Biagio A; Rosso R; Beltrame A; Bassetti D
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):343-52. PubMed ID: 15954851
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
Wilcox MH
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
[TBL] [Abstract][Full Text] [Related]
18. Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae.
Ijzerman MM; Tack KJ; Huang DB
Clin Ther; 2010 Dec; 32(13):2198-206. PubMed ID: 21316536
[TBL] [Abstract][Full Text] [Related]
19. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
Pulay I; Konkoly TM; Zsirka KA; Csapó Z; Flautner L; Tihanyi T
Orv Hetil; 2003 Jan; 144(1):29-33. PubMed ID: 12635350
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
